STAGE IVA PROSTATE CANCER AJCC V8
Clinical trials for STAGE IVA PROSTATE CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IVA PROSTATE CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IVA PROSTATE CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Major trial tests tailored hormone therapy to control prostate cancer
Disease control OngoingThis large study aims to personalize treatment for men with high-risk prostate cancer. Based on a genetic test score, patients receive either a shorter course of hormone therapy (to reduce side effects) or a stronger hormone therapy regimen (to better control aggressive cancer), …
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
Shorter radiation course tested for prostate cancer recovery
Disease control OngoingThis study compares two radiation schedules given after prostate cancer surgery. It tests whether a shorter, more intense 4.5-week course works as well as the standard 7-week course at keeping cancer from returning. Researchers will track side effects and quality of life for up t…
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New drug combo tested for Tough-to-Treat advanced cancers
Disease control OngoingThis early-stage study is testing a new combination of two drugs, AZD8186 and docetaxel, for patients with advanced solid tumors that have specific genetic changes (PTEN or PIK3CB mutations). The main goals are to find the safest and most effective dose and to understand the side…
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New Two-Drug attack on tough, spreading cancers
Disease control OngoingThis early-stage study is testing a new combination of two drugs, DS3201 and ipilimumab, for people with advanced prostate, bladder, or kidney cancer that has spread. The main goals are to find the safest dose and understand the side effects. Researchers hope the drug combo will …
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New drug combo tested to control aggressive prostate cancer spread
Disease control OngoingThis study is testing whether a combination of three drugs can help control prostate cancer that has spread to other parts of the body. Researchers want to see if they can predict which patients will respond best to this treatment by analyzing tumor characteristics. The trial inv…
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
New immune therapy cocktail tested in fight against advanced cancers
Disease control OngoingThis study is testing the safety and effectiveness of avelumab, an immunotherapy drug, when given in combination with other immune-boosting drugs and sometimes radiation. It is for patients with advanced solid tumors that have spread and who have run out of standard treatment opt…
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:29 UTC
-
New drug duo aims to outsmart advanced prostate cancer
Disease control OngoingThis study is testing if adding a drug called rucaparib to standard treatment (enzalutamide) works better for men whose prostate cancer has spread and stopped responding to hormone therapy. The goal is to see if the combination helps patients live longer or keeps their cancer fro…
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
Could prostate cancer patients take a break from harsh hormone drugs?
Disease control OngoingThis study is testing whether men with advanced prostate cancer that has spread can safely take a break from hormone-blocking medications when their cancer responds exceptionally well to treatment. The trial involves 79 men who have been on strong hormone therapy for 18-24 months…
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Mar 13, 2026 15:05 UTC